OverviewSuggest Edit

4SC is a biopharmaceutical company developing small-molecule drugs that target key indications in cancer with unmet medical needs. Its current product pipeline includes two programs in clinical development: resminostat, an orally administered histone deacetylase (HDAC) inhibitor with a mechanism of action that represents a therapy for a spectrum of oncology indications, both in monotherapy and in combination with other anti-cancer drugs); and domatinostat, an orally administered histone deacetylase (HDAC) inhibitor with a mode of action that was designed to strengthen the body’s own anti-tumor immune response.

TypePublic
Founded1997
HQPlanegg, DE
Website4sc.de

Latest Updates

Employees (est.) (Sept 2020)46(+5%)
Revenue (FY, 2019)€2.2 M(-47%)
Share Price (Sept 2021)€5.2(+4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at 4SC

Jason Loveridge

Jason Loveridge

Chief Executive Officer (CEO) Chairman of the Management Board
Frank Hermann

Frank Hermann

Chief Development Officer (CDO)
Susanne Danhauser-Riedl

Susanne Danhauser-Riedl

Chief Medical Officer (CMO)
Show more

4SC Office Locations

4SC has an office in Planegg
Planegg, DE (HQ)
Fraunhoferstraße 22
Show all (1)

4SC Financials and Metrics

4SC Revenue

Embed Graph
View revenue for all periods
4SC's revenue was reported to be €2.2 m in FY, 2019 which is a 47.4% decrease from the previous period.
EUR

Revenue (FY, 2019)

2.2m

Revenue growth (FY, 2018 - FY, 2019), %

(47.4%)

Gross profit (FY, 2019)

1.9m

Gross profit margin (FY, 2019), %

84.3%

Net income (FY, 2019)

(14.0m)

EBIT (FY, 2019)

(13.9m)

Market capitalization (21-Sept-2021)

263.5m

Closing stock price (21-Sept-2021)

5.2

Cash (31-Dec-2019)

31.7m
4SC's current market capitalization is €263.5 m.
Annual
EURFY, 2017FY, 2018FY, 2019

Revenue

4.2m4.2m2.2m

Revenue growth, %

(1%)(47%)

Cost of goods sold

574.0k343.0k345.0k

Gross profit

3.6m3.8m1.9m
Half Year
EURH1, 2017H1, 2018H1, 2019

Revenue

936.0k4.1m2.0m

Cost of goods sold

90.0k269.0k253.0k

Gross profit

846.0k3.8m1.8m

Gross profit Margin, %

90%93%88%
Annual
EURFY, 2017FY, 2018FY, 2019

Cash

41.3m25.0m31.7m

Accounts Receivable

30.0k14.0k46.0k

Prepaid Expenses

109.0k183.0k122.0k

Current Assets

41.5m25.6m46.2m
Half Year
EURH1, 2017H1, 2018H1, 2019

Cash

4.6m34.1m17.8m

Accounts Receivable

355.0k1.0m1.9m

Current Assets

5.5m35.6m21.2m

PP&E

211.0k612.0k2.5m
Annual
EURFY, 2017FY, 2018FY, 2019

Depreciation and Amortization

899.0k841.0k1.1m

Accounts Payable

341.0k(55.0k)374.0k

Cash From Operating Activities

(8.5m)(16.2m)(12.7m)

Purchases of PP&E

(168.0k)(120.0k)(133.0k)
Half Year
EURH1, 2017H1, 2018H1, 2019

Depreciation and Amortization

430.0k419.0k555.0k

Accounts Payable

(99.0k)(252.0k)96.0k

Cash From Operating Activities

(5.4m)(7.1m)(6.9m)

Purchases of PP&E

(23.0k)(90.0k)(43.0k)
EURH1, 2017

Revenue/Employee

22.6k

Financial Leverage

0.7 x
Show all financial metrics

4SC Revenue Breakdown

Embed Graph

4SC revenue breakdown by business segment: 100.0% from Asia

4SC Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

4SC Online and Social Media Presence

Embed Graph

4SC News and Updates

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838

NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE...

Chronic Lymphocytic Leukemia Treatment 2018 Global Market Key Players – 4SC, AbbVie, ACEA Biosciences, ADC Therapeutics, Aeglea BioTherapeutics – Analysis and Forecast to 2025

WiseGuyRerports.com Presents “Global Chronic Lymphocytic Leukemia Treatment Market Size, Status and Forecast 2018-2025” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

4SC Frequently Asked Questions

  • When was 4SC founded?

    4SC was founded in 1997.

  • Who are 4SC key executives?

    4SC's key executives are Jason Loveridge, Frank Hermann and Susanne Danhauser-Riedl.

  • How many employees does 4SC have?

    4SC has 46 employees.

  • What is 4SC revenue?

    Latest 4SC annual revenue is €2.2 m.

  • What is 4SC revenue per employee?

    Latest 4SC revenue per employee is €47.7 k.

  • Who are 4SC competitors?

    Competitors of 4SC include Imago BioSciences, Italfarmaco and Achilles Therapeutics.

  • Where is 4SC headquarters?

    4SC headquarters is located at Fraunhoferstraße 22, Planegg.

  • Where are 4SC offices?

    4SC has an office in Planegg.

  • How many offices does 4SC have?

    4SC has 1 office.